Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
Cipla is currently trading at Rs. 316.00, up by 2.00 points or 0.64% from its previous closing of Rs. 314.00 on the BSE.
The scrip opened at Rs. 317.80 and has touched a high and low of Rs. 318.20 and Rs. 315.70 respectively. So far 12,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 359.00 on 07-Feb-2012 and a 52 week low of Rs. 273.60 on 06-Sep-2011.
Last one week high and low of the scrip stood at Rs. 324.60 and Rs. 313.20 respectively. The current market cap of the company is Rs. 25,372.00 crore.
The promoters holding in the company stood at 36.80% while Institutions and Non-Institutions held 33.27% and 29.84% respectively.
Cipla, one of the world’s leading generic pharmaceutical companies in collaboration with Drugs for Neglected Diseases Initiative (DNDi) is planning to launch the Fixed-Dose combination of ‘Artesunate (AS)1 + Mefloquine (MQ)2’ for the treatment of uncomplicated P. falciparum malaria. The combination of AS and MQ is proven to be a safe, rapid and reliably effective treatment for uncomplicated P. falciparum malaria and is recommended by the World Health Organization (WHO).
Targeted as an option for treating resistant uncomplicated falciparum malaria, the new combination simplifies the patient’s treatment with a single dose of 1 or 2 tablets for 3 days, ensuring that the drugs are taken together and in correct proportions. This new fixed-dose combination treatment will be introduced in India under the brand name ‘MEFLIAM Plus’.
Through an innovative partnership supported and facilitated by DNDi in 2008, Cipla entered into an agreement with the Brazilian government-owned pharmaceutical company Farmanguinhos/Fiocruz to introduce the new fixed-dose combination in Asian and African countries. The product will be launched in India and Malaysia soon where it has already been registered.
The drugs for the fixed-dose combination (ASMQ) are being manufactured in Cipla’s world class manufacturing unit in Patalganga, which are approved by WHO-Geneva, USFDA, MHRA-UK and various other regulatory bodies.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1464.85 |
| Dr. Reddys Lab | 5955.65 |
| Cipla | 1477.15 |
| Zydus Lifesciences | 1050.35 |
| Lupin | 1603.55 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
